14559-12-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its antifungal and antiproliferative properties make it a valuable component in developing new drugs for medical applications.
Used in Agrochemical Industry:
In the agrochemical sector, Ethyl 4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate serves as a fundamental building block in the creation of agrochemicals. Its incorporation aids in the development of products designed to protect crops and enhance agricultural yields.
Used in Drug Development:
Ethyl 4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate is utilized in drug development for its potential to contribute to the creation of new medicinal compounds. Ongoing research explores its capacity to be integrated into treatments for a variety of health conditions, underscoring its importance in advancing medical science.

Upstream product

• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 105-56-6 ethyl 2-cyanoacetate 
• 108-94-1 cyclohexanone 

Downstream Products

• 19156-54-8 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid 
• 851634-60-1 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbaldehyde 

Relevant academic research and scientific papers

Ethyl 2-Aminothiophene-3-Carboxylates in the Synthesis of Isomeric Thienopyridines

A convenient method for the synthesis of thieno[3,2-c]pyridinones was developed. A number of thiophene derivatives was prepared, and the possibility of using thiophene desamino derivatives for the design of potentially biologically active molecules was demonstrated.

Thieno[3,2-c]pyran-4-one based novel small molecules: Their synthesis, crystal structure analysis and in vitro evaluation as potential anticancer agents

Novel thieno[3,2-c]pyran-4-one based small molecules were designed as potential anticancer agents. Expeditious synthesis of these compounds was carried out via a multi-step sequence consisting of few steps such as Gewald reaction, Sandmeyer type iodination, Sonogashira type coupling followed by iodocyclization and then Pd-mediated various C-C bond forming reactions. The overall strategy involved the construction of thiophene ring followed by the fused pyranone moiety and then functionalization at C-7 position of the resultant thieno[3,2-c]pyran-4-one framework. Some of the compounds synthesized showed selective growth inhibition of cancer cells in vitro among which two compounds for example, 5d and 6c showed IC50 values in the range of 2.0-2.5 μM. The crystal structure analysis of an active compound along with hydrogen bonding patterns and molecular arrangement present within the molecule is described.

Fused bicyclic amide compounds and medicinal use thereof

The present invention provides a compound represented by the formula (I) wherein ring A is benzene, cyclohexane, pyridine, piperidine or a derivative thereof, imidazole or a derivative thereof and the like, ring B is benzene, cyclohexane, pyrrole or a derivative thereof, furan, thiophene and the like, R1, R2 and R3 are each hydrogen, alkyl, halogen, hydroxyl group, alkoxy and the like, W is hydrogen, alkyl or hydroxycarbonylalkyl, X is halogen, cyano, nitro and the like, X′ is hydrogen, halogen and the like, and Y is alkyl, hydroxyalkyl, hydroxycarbonylalkyl, aminoalkyl and the like, a salt thereof, and a pharmaceutical agent containing the compound. The compound of the present invention shows a superior inhibitory effect on the proliferation of activated lymphocyte and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-dimethylbicyclo[3.1.1]heptane derivatives

In an earlier paper, we reported that novel prostaglandin D2 (PGD2) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD2 receptor antagonists having the 6,6-dimethylbicyclo [3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD2 receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.